Vaccines Archives

News and Trends 21 Mar 2023

Etana secures funding for oncology pipeline

PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has secured a new round of investment led by DEG followed by Yunfeng Capital, HighLight Capital and East Ventures. The round of financing will be used for further strengthening PT Etana Biotechnologies’ pipeline and portfolio especially in oncology. Currently, PT Etana Biotechnologies focuses on local biopharmaceutical production […]

March 21, 2023 - 2 minutesmins - By Jim Cornall

Best in Biotech 21 Mar 2023

5 advancements in Down syndrome research over the past year

It was in 1959 when an extra chromosome on the 21st pair in the human cell was discovered by French geneticist Jerome Jean Louis Marie Lejeune. This was followed by research in the discipline of cytogenetics – the study of chromosomes. This chromosomal aberration which affects around one in 1000 live births worldwide, is called […]

March 21, 2023 - 8 minutesmins - By Roohi Mariam Peter

News and Trends 20 Mar 2023

SpyBiotech receives more than $4 million to develop vaccine platform

UK-based SpyBiotech has received a grant of more than $4 million from the Bill & Melinda Gates Foundation to build its SpyVector platform for the development of a cross-protective coronavirus vaccine. The platform, which is based on recombinant adenovirus – a viral vector which can induce cellular immunity – enables a covalent decoration with the […]

March 20, 2023 - 2 minutesmins - By Roohi Mariam Peter

News and Trends 17 Mar 2023

Likang gets trial ok for China’s first personalized cancer vaccine

Likang Life Sciences has received implied approval for the clinical trial of its personalized neoantigen-targeted vaccine for advanced solid tumors, LK101 injection. This is the first personalized neoantigen vaccine and mRNA editing product approved by China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to enter the clinical stage. Likang submitted […]

March 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 Mar 2023

Beyond Biotech podcast 37: Natural killer cells, biopharma revenue, toxic shock syndrome vaccine

This week our guests are Marit Inngjerdingen from the Institute of Clinical Medicine in Norway; Kyle Forcier, senior director of life sciences product marketing at Model N; and Dr. Andreas Roetzer, head of R&D for vaccines at Biomedical Research & Bio-Products. The next breakthrough in cancer treatment? In our body, we have an innate immune […]

March 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 24 Feb 2023

AELIX announces ‘important step towards HIV eradication’

AELIX Therapeutics S.L., a clinical-stage biotechnology company specializing in the discovery and development of immunotherapies for HIV infection, has announced positive topline results from its AELIX-003 trial. The study evaluated the safety, tolerability, immunogenicity and efficacy of AELIX Therapeutics’ HTI T-cell therapeutic HIV vaccine in combination with Gilead’s investigational Toll-Like Receptor 7 (TLR7) agonist, vesatolimod […]

February 24, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 17 Feb 2023

Immuno Cure starts HIV drug trial

Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park, which specializes in PD-1-enhanced DNA vaccines and immunotherapies, has started its phase I clinical trial of ICVAX, a therapeutic vaccine against HIV/AIDS. The trial is taking place at the National Clinical Research Center for Infectious Diseases at The Third People’s […]

February 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

Scancell looking to partner after positive COVID vaccine data

Scancell Holdings plc, which develops novel immunotherapies for the treatment of cancer and infectious disease, has announced preliminary immunogenicity data from its phase 1 COVIDITY clinical trial at the University of Cape Town (UCT) Lung Institute in South Africa. The objectives of the trial were to assess the safety and immunogenicity of two vaccine candidates, […]

February 14, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

First toxic shock syndrome vaccine phase 2 study completed

The first vaccine to potentially prevent Staphylococcal-induced toxic shock syndrome (TSS) has successfully completed a phase 2 study. TSS is a life-threatening condition caused by toxins that can lead to multiple organ failure and death. Nosocomial pathogen methicillin-resistant Staphylococcus aureus (MRSA) bacteria are resistant to widely-used antibiotics. Infections with MRSA are harder to treat and […]

February 9, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

Cleveland Clinic breast cancer vaccine study moves forward

Researchers from global health system Cleveland Clinic have launched the next step in their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease. Funded by the U.S. Department of Defense, the new phase 1b study will enroll cancer-free individuals at high risk for developing […]

February 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

AAHI bags $9.9M to develop nasal spray influenza RNA vaccine

The Access to Advanced Health Institute (AAHI) has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA) to develop a prototype intranasal bivalent influenza RNA vaccine candidate. The candidate will be based on AAHI’s self-amplifying RNA (saRNA) platform, which targets both pandemic A(H5N1) […]

February 7, 2023 - 3 minutesmins - By Jim Cornall

Interview 23 Jan 2023

Watch: pHion Therapeutics talks about next-generation mRNA vaccines

pHion Therapeutics is a U.K.-based vaccine development company. It is developing a pipeline of therapeutic and prophylactic vaccines focussed on viral infections and oncology. The company’s proprietary RALA platform can deliver anionic molecules, such as mRNA and DNA, in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. The RALA peptide-based […]

January 23, 2023 - 1 minutemin - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us